Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with ...

Shares of Corcept Therapeutics (CORT) jumped ~25% in the premarket on Thursday after the maker of Korlym tablets announced ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim ...

Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) ...

Women with certain genetic mutations are at extremely high risk of ovarian cancer. Now, some researchers are trying a new ...

The investigational cortisol modulator relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian ...

Differentiating palliative care from hospice is crucial; palliative care focuses on holistic treatment, while hospice ...

Eli Lilly and Co. has received the Federal Drug Administration’s breakthrough therapy designation for a drug in development ...

NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in younger women.

A major development has emerged in the long-running Johnson Johnson talc litigation, marking a significant moment for tens of ...

A systematic review found that bilateral salpingectomy is associated with roughly an 80% reduction in risk for the serous ...

Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant ...